Holen Sie sich die Stockscreener-App
0.385
8.20%
-0.0344
Schlusskurs vom Vortag:
$0.4194
Offen:
$0.41
24-Stunden-Volumen:
1.05M
Relative Volume:
1.12
Marktkapitalisierung:
$7.45M
Einnahmen:
$420.00K
Nettoeinkommen (Verlust:
$-19.65M
KGV:
-0.00278
EPS:
-138.243
Netto-Cashflow:
$-26.08M
1W Leistung:
-19.05%
1M Leistung:
-26.32%
6M Leistung:
-95.48%
1J Leistung:
-99.50%
1-Tages-Spanne:
$0.3803
$0.42
1-Wochen-Bereich:
$0.3803
$0.54
52-Wochen-Spanne:
$0.3803
$95.50
Kala Bio Inc Stock (KALA) Company Profile
Firmenname
Kala Bio Inc
Sektor
Branche
Telefon
781-996-5252
Adresse
1167 MASSACHUSETTS AVENUE, ARLINGTON, MA
Compare KALA vs VRTX, MRNA, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KALA
Kala Bio Inc
|
0.385 | 9.20M | 420.00K | -19.65M | -26.08M | -138.24 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Kala Bio Inc Stock (KALA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-30 | Herabstufung | Mizuho | Outperform → Neutral |
| 2025-09-29 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-09-29 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2025-09-08 | Eingeleitet | Mizuho | Outperform |
| 2025-07-11 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2022-03-30 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2021-08-06 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-09-14 | Herabstufung | Jefferies | Buy → Hold |
| 2020-07-23 | Eingeleitet | Northland Capital | Outperform |
| 2020-06-01 | Fortgesetzt | Oppenheimer | Outperform |
| 2020-05-27 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-09 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-12-17 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-03-14 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Kala Bio Inc Aktie (KALA) Neueste Nachrichten
KALA BIO stock targets telehealth expansion with a USD 15.00 million LOI - AD HOC NEWS
Why FingerMotion Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket - Benzinga
KALA Bio (KALA) Shares Soar 57% After Hours: Here's Why - Benzinga
Kala Bio signs letter of intent to acquire telehealth firm - Investing.com
KALA Bio Inc.: KALA Bio Signs Non-Binding LOI to Acquire Nationwide Telehealth Platform with Approximately $48 Million in Sales Since Inception - FinanzNachrichten.de
KALA BIO, Inc. (KALA) Signs LOI to Buy Telehealth MSO for ~$15M - TradingView
Kala Pharmaceuticals Inc (NYSE: KALA) Share Price, KALA Stock News, KALA Share Price & Updates - kalkine.ca
Form DEF 14A KALA BIO For: 25 September By Investing.com - Investing.com Nigeria
Kala Bio (KALA) Expands Genomic Testing Distribution with New Le - GuruFocus
Kala Bio signs letter of intent to expand genetic testing deal - Investing.com
A U.S. DNA platform may resell Virotek's genetic tests beyond eye care. - Stock Titan
KALA BIO Adds Yenvy Truong as Advisor to Support Growth and Acquisitions - citybiz
KALA BIO Adds Healthcare Operator Yenvy Truong to Advisory Team - Yahoo Finance
Reverse stock split heads to a vote at KALA BIO (NASDAQ: KALA) - Stock Titan
Kala Bio signs exclusive US distribution deal with Virotek for ophthalmology genetic testing - Investing.com India
Kala Bio Secures Exclusive Ophthalmic Genetic Testing Deal - TipRanks
Kala Bio Secures 5-Year Exclusive U.S. Distribution for Ophthalmic Genetic Testing With Virotek - TradingView
KALA BIO, Inc. Enters Exclusive Distribution And Reseller Agreement With Virotek, Inc - marketscreener.com
KALA BIO (NASDAQ: KALA) Announces November 3, 2026 Annual Meeting and September 19 Proposal Deadline - Kalkine Media
KALA BIO Updates Annual Meeting and Proposal Deadlines - TipRanks
KALA BIO (NASDAQ: KALA) sets Sept. 19 cutoff for 2026 shareholder proposals - Stock Titan
KALA Q4 2025 Earnings: Narrowed Loss Delivers Major Beat Despite Revenue AbsenceRevenue Recognition Risk - dars.gov.et
Kala Bio secures exclusive U.S. rights to Virotek genetic tests By Investing.com - Investing.com Nigeria
KALA Stock Update: Exclusive U.S. Distribution Deal with Virotek Highlights Growth Challenges - GuruFocus
Kala Bio Signs Exclusive U.S. Distribution Agreement for Virotek Ophthalmology Genetic Tests - Yahoo Finance
Kala Bio secures exclusive U.S. rights to Virotek genetic tests - Investing.com
Kala Bio and Virotek Finalize Definitive Agreement - GlobeNewswire
For one year, eye-condition genetic tests will have one U.S. seller, Kala Bio. Virotek still processes samples. - Stock Titan
Kala Bio Targets Near-Term Revenue With Virotek Ophthalmology Genetic Testing Partnership - finance.yahoo.com
Kala Bio, Virotek enters LOI for distribution agreement - TipRanks
KALA Bio (KALA) Signs Exclusive Distribution LOI with Virotek, F - GuruFocus
Kala Bio, Virotek Outline Exclusive U.S. Genetic Testing | KALA Stock News - Stock Titan
Kala Bio and Virotek Announce Letter of Intent to Establish an Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program - The Manila Times
KALA BIO Faces Nasdaq Listing Compliance Uncertainty - The Globe and Mail
KALA BIO Faces Nasdaq Delisting Risk on Minimum Bid Price Failure - Minichart
KALA BIO Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
KALA (KALA) Close: Ends Down by 2.39% at $0.82 at the Close; Boundary Watch: Traders Can Monitor the $0.78-$0.86 Range in the Latest ReadingLow Vol ETF - vinanet.vn
KALA (KALA) Technicals: Moves 6.67% Down to $0.84; Technical Setup: the Supplied Trading Band Runs From $0.80 to $0.88 at the CloseProtective Put - vinanet.vn
KALA Stock Hits Record Low – Firm Announces Reverse Split After Shares Fail To Surpass The $1 Mark - Stocktwits
KALA BIO: Q2 Earnings Snapshot - AOL.com
KALA BIO Q2 Net Loss Narrows to $1.58 Million Amid Sharp Spending Cuts - Minichart
KALA BIO, Inc. Q2 2026: Net loss $(1.58M), EPS $(21.32) — 10-Q Summary - TradingView
KALA: Net loss narrowed sharply as focus shifted to AI platform, with liquidity supported by note receivable - TradingView
KALA BIO (KALA) pivots to biotech AI with $229K on hand - Stock Titan
KALA (KALA) Session: Retreats 0.97% to $0.89; Next Session: Price Remains Between $0.85 Support and $0.93 Resistance in the Latest ReadingRTH Profile - vinanet.vn
KALA Q4 2025 Earnings: Loss Narrows to -33.5 Per Share, Beating Estimates by 54.38Performance Review - vinanet.vn
KALA BIO Announces Brief Delay in Quarterly Filing - TipRanks
KALA BIO (KALA) delays June 30, 2026 Form 10-Q to finalize liquidity analysis - Stock Titan
KALA Q4 2025 Earnings: Narrower-Than-Expected Loss Delivers a 54.38 EPS SurpriseDividend Growth Analysis - vinanet.vn
KALA BIO Inc (KALA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
KALA BIO (KALA) Climbs 4.4% to $0.73 as Bulls Target $0.77 ResistanceRelative Volume - dars.gov.et
Finanzdaten der Kala Bio Inc-Aktie (KALA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):